| Name | Title | Contact Details |
|---|
Bioventus®Inc. (Nasdaq: BVS) develops Innovations for Active Healing and its mission is to make a difference by helping patients resume and enjoy active lives. The Company has products for pain treatment & joint preservation, restorative therapies and bone graft substitutes. Established in 2012, Bioventus is headquartered in Durham, NC. The company has more than 800 employees worldwide and its international headquarters is in Hoofddorp, The Netherlands. Bioventus also has offices in Memphis, TN, Valencia, CA, Hod Hasharon, Israel and Mississauga, Ontario, Canada. Bioventus works with patients, payers and health care providers throughout the world.
Bovie Medical is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kryosphere is a Durham, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery` diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology` services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65`000 employees have a passion and commitment to help improve patient outcomes` improve the safety and efficiency of clinicians` care delivery process` enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers` BD can help enhance outcomes` lower costs` increase efficiencies` improve safety and expand access to health care. In 2017` BD welcomed C. R. Bard and its products into the BD family.
LuxCath is the leader in using fluorescence and optics to directly view lesions during cardiac ablation procedures. The company`s breakthrough technology offers the potential for dramatic evolution in the way ablation procedures are performed by assessing tissue contact and enabling direct lesion progression monitoring. LuxCath`s patented solution aims to ensure the quality of catheter lesions at the moment they are made. LuxCath enables constant optical tissue contact assessment and provides valuable lesion formation and progression information during each ablation.